...
【24h】

Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.

机译:手术对中肠类癌伴淋巴结转移和肝转移的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

We have evaluated survival and tumor-related symptoms in the presence of mesenteric lymph node and liver metastases in relation to surgical procedures in 314 patients (148 women, mean age at diagnosis 61 years; 249 with liver metastases) treated for midgut carcinoid tumors. Of the operated patients, 46% presented with severe abdominal pain and intestinal obstruction and were operated on before the diagnosis. Medical treatment (somatostatin analogs, interferon-a) was initiated in 67% and 86%, respectively. Surgical attempts included small intestine or ileocecal/right-sided colon resection with excision of mesenteric lymph node metastases. Most of the patients (n = 286) had mesenteric lymph node metastases; 33% of them had unresectable mesenteric lymph node metastases and underwent surgery without mesenteric dissection. Patients who underwent resection for the primary tumor had a longer survival than those with no resection (median survival 7.4 vs. 4.0 years; p <0.01). Patients who underwent successful excision of mesenteric metastases had a significantly longer survival than those with remaining lymph node metastases. Patients operated on for a primary tumor but with remaining lymph nodes but no liver metastases and who subsequently received interferon and somatostatin analog treatment had a median survival of 7.4 years. Resection of the primary tumor and the mesenteric lymph node metastases led to a significant reduction in tumor-related symptoms. Surgery to remove the primary intestinal tumor including mesenteric lymph node metastases is supported by the present results, even in the presence of liver metastases. Liver metastases and significant preoperative weight loss are identified as major negative prognostic factors for survival.
机译:我们评估了314例中肠类癌患者(其中148例女性,诊断时平均年龄61岁; 249例有肝转移)的肠系膜淋巴结转移和肝转移相关的生存和与肿瘤相关的症状。在接受手术的患者中,有46%出现严重的腹痛和肠梗阻,并在诊断前进行了手术。分别有67%和86%的人开始接受药物治疗(somatostatin类似物,α-干扰素)。手术尝试包括小肠切除或回盲肠/右侧结肠切除,并切除肠系膜淋巴结转移。大多数患者(n = 286)有肠系膜淋巴结转移。其中33%的患者有无法切除的肠系膜淋巴结转移,并且接受了未经肠系膜清扫术的手术。接受原发肿瘤切除术的患者比没有切除术的患者具有更长的生存期(中位生存期7.4 vs. 4.0年; p <0.01)。进行了成功切除肠系膜转移的患者的生存期显着长于其余淋巴结转移的患者。接受原发肿瘤手术但仍有淋巴结残留但无肝转移的患者,随后接受干扰素和生长抑素类似物治疗,中位生存期为7.4年。切除原发肿瘤和肠系膜淋巴结转移可显着减少肿瘤相关症状。即使在存在肝转移的情况下,本结果也支持手术切除包括肠系膜淋巴结转移在内的原发性肠道肿瘤。肝转移和术前体重明显减轻是生存的主要负面预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号